Connect with us

Hi, what are you looking for?

Health

FDA chief calls for probe of relationship between agency and Biogen

FDA chief calls for probe of relationship between agency and Biogen

The Food and Drug Administration’s acting commissioner has called for a watchdog probe of her agency’s dealings with the drugmaker Biogen prior to last month’s accelerated approval of a new Alzheimer’s therapy from the company.

The decision to greenlight Aduhelm has drawn widespread scrutiny, and came over the objections of independent advisers to the FDA and other experts who said there was little evidence of its effectiveness. STAT reported that FDA officials worked with Biogen executives to help get the drug, which has an annual cost of $56,000, on the market.

The review by the Department of Health and Human Services inspector general will establish “whether any interactions that occurred between Biogen and FDA review staff are inconsistent with FDA policies and procedures,” acting commissioner Janet Woodcock wrote in a letter made public Friday. It would also assuage concerns about any kind of inappropriate relationship between the agency and a company it regulates, Woodcock wrote.

You May Also Like

World

France, which has opened its borders to Canadian tourists, is eager to see Canada reopen to the French. The Canadian border remains closed...

Health

Kashechewan First Nation in northern Ontario is experiencing a “deepening state of emergency” as a result of surging COVID-19 cases in the community...

World

The virus that causes COVID-19 could have started spreading in China as early as October 2019, two months before the first case was identified in the central city of Wuhan, a new study...

World

April Ross and Alix Klineman won the first Olympic gold medal for the United States in women’s beach volleyball since 2012 on Friday,...